🇺🇸 FDA
Patent

US 6667313

8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators

expired A61PA61P13/08A61P15/00

Quick answer

US patent 6667313 (8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators) held by Ligand Pharmaceuticals Incorporated expires Mon Dec 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Dec 23 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P13/08, A61P15/00, A61P15/08, A61P17/00